Canada Markets open in 2 hrs 55 mins

Entheon Biomedical Corp. (ENTBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2110-0.0090 (-4.09%)
At close: 03:47PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.2200
Open0.2138
BidN/A x N/A
AskN/A x N/A
Day's Range0.1907 - 0.2189
52 Week Range0.1907 - 1.5000
Volume35,803
Avg. Volume65,198
Market Cap13.042M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee

    Vancouver, British Columbia--(Newsfile Corp. - January 6, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced the submission of the regulatory package for its upcoming Phase 1 Clinical trial, EBRX-101, to the ethics committee of the BEBO Foundation for the Assessment

  • Baystreet

    Stocks in play: Entheon Biomedical Corp.

    Announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, ...

  • Newsfile

    Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel

    Subsidiary HaluGen Life Sciences has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca Vancouver, British Columbia--(Newsfile Corp. - December 21, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased